Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (541-550 of 560) with videos related to

Pageof 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year UpdateChae Young Han, Karen H Lu, Gwen Corrigan, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Clinical Chemistry|December 2, 2008
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancersCatharine M Sturgeon, Michael J Duffy, Ulf-Håkan Stenman, et al.
Cancers|July 24, 2021
Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian CancerChae Young Han, David A Patten, Se Ik Kim, et al.
JAMA Network Open|October 14, 2022
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic CharacteristicsKatelyn F Handley, Travis T Sims, Nicholas W Bateman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancerClaire S Zhu, Paul F Pinsky, Daniel W Cramer, et al.
Nature Communications|June 10, 2022
Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylationYiyan Zheng, Ritika Sethi, Lingegowda S Mangala, et al.
Plos Genetics|June 5, 2020
In vivo modeling of metastatic human high-grade serous ovarian cancer in miceOlga Kim, Eun Young Park, David L Klinkebiel, et al.
Nature Communications|February 4, 2018
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylationYiyan Zheng, Ritika Sethi, Lingegowda S Mangala, et al.
JCI Insight|May 4, 2021
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Kenta Masuda, Zhiyuan Hu, et al.
Pageof 56

Showing results (541-550 of 560) with videos related to

Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year UpdateChae Young Han, Karen H Lu, Gwen Corrigan, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Clinical Chemistry|December 2, 2008
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancersCatharine M Sturgeon, Michael J Duffy, Ulf-Håkan Stenman, et al.
Cancers|July 24, 2021
Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian CancerChae Young Han, David A Patten, Se Ik Kim, et al.
JAMA Network Open|October 14, 2022
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic CharacteristicsKatelyn F Handley, Travis T Sims, Nicholas W Bateman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|March 5, 2011
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancerClaire S Zhu, Paul F Pinsky, Daniel W Cramer, et al.
Nature Communications|June 10, 2022
Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylationYiyan Zheng, Ritika Sethi, Lingegowda S Mangala, et al.
Plos Genetics|June 5, 2020
In vivo modeling of metastatic human high-grade serous ovarian cancer in miceOlga Kim, Eun Young Park, David L Klinkebiel, et al.
Nature Communications|February 4, 2018
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylationYiyan Zheng, Ritika Sethi, Lingegowda S Mangala, et al.
JCI Insight|May 4, 2021
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Kenta Masuda, Zhiyuan Hu, et al.
Pageof 56